Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 11/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 3/20 | 0.34 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14128414 | 0.81 | SLC5A2 (0.53) | SLC5A2SLC5A1 | |
| SCHEMBL28534298 | 0.79 | SLC5A2 (0.37) | SLC5A2SLC6A4HTR2AKCNH2SLC5A1 | |
| SCHEMBL12782162 | 0.75 | CCR5 (0.47) | SLC6A4HTR2AKCNH2CCR5 | |
| SCHEMBL10040915 | 0.74 | SLC5A2 (0.42) | SLC5A2SLC5A1 | |
| SCHEMBL30137005 | 0.74 | SLC5A2 (0.42) | SLC5A2SLC5A1 | |
| SCHEMBL500031 | 0.74 | SLC6A4 (0.37) | SLC5A2SLC6A4HTR2AKCNH2CCR5 | |
| SCHEMBL500175 | 0.73 | CA2 (0.38) | SLC5A2SLC6A4HTR2AKCNH2SLC5A1 | |
| SCHEMBL17842 | 0.72 | MEN1 (0.46) | SLC5A2SLC6A4HTR2AKCNH2CCR5 | |
| SCHEMBL37715 | 0.72 | SLC5A2 (0.47) | SLC5A2SLC6A4HTR2AKCNH2CCR5 | |
| SCHEMBL1457579 | 0.72 | APP (0.40) | SLC5A2SLC6A4HTR2AKCNH2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108203432-B | Glucopyranosyl derivative and application thereof in medicine | 宜昌东阳光长江药业股份有限公司 | 2021-03-02 | — | — | CN | disclosed |